Cryoport, Inc., the cryogenic logistics company dedicated to the life sciences industry, has announced that it will assist Sanaria Inc. in the design and implementation of the cryogenic cold chain for Sanaria’s investigational malaria vaccines.

The Cryoport designs will incorporate distribution models enabling ‘just in time’ delivery by providing logistics support incorporating novel packaging designs, inventory management, liquid nitrogen (LN2) replenishment and will test transport to specific clinics.

Cryoport’s SmartPak II monitoring system will be utilised to manage in real time the ‘chain of custody’ distribution logistics as well as the ‘chain of condition’ environmental conditions. The SmartPak II works alongside Cryoport’s Cryoportal™ software system to provide comprehensive logistics monitoring, including GPS tracking, which locates dry shippers and payloads and proactively tracks potential adverse events which may occur due to weather, logistics handling, or other delays.

Jerrell Shelton, CEO of Cryoport, commented, “We are thrilled to have been selected to develop models for the distribution of Sanaria’s groundbreaking malaria vaccine as part of these two projects. This selection, we believe, is a testament to the quality and reliability of our cryogenic logistics solutions. We are proud to support Sanaria’s work developing and eventually bringing to market a vaccine to prevent malaria.”

Dr. Stephen L. Hoffman, CEO and Scientific Officer of Sanaria stated, “Cryoport’s expertise in cryogenic logistics management, track record and reputation were important in helping to secure funding from the US DoD and NIAID, NIH. Cryoport has reliably supported our research efforts over the past five years and they were the natural partner for these new projects.”

Liquid nitrogen cryogenic